Skip to content
Iopromide
Ultravist (iopromide) is a small molecule pharmaceutical. Iopromide was first approved as Ultravist 370 on 1995-05-10.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Ultravist
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iopromide
Tradename
Company
Number
Date
Products
ULTRAVIST 370BayerN-020220 RX1995-05-10
1 products, RLD, RS
ULTRAVIST 300BayerN-020220 RX1995-05-10
1 products, RLD, RS
ULTRAVIST (PHARMACY BULK)BayerN-021425 RX2002-09-20
2 products, RLD, RS
Show 4 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
ultravistNew Drug Application2022-02-22
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V08: Contrast media
— V08A: X-ray contrast media, iodinated
— V08AB: Watersoluble, nephrotropic, low osmolar x-ray contrast media
— V08AB05: Iopromide
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—11—1—2
Coronary stenosisD023921EFO_1000882———2—2
Arterial occlusive diseasesD001157EFO_0009085———2—2
Renal insufficiencyD051437HP_0000083N19———2—2
Diabetes mellitusD003920EFO_0000400E08-E13———2—2
HypothyroidismD007037EFO_0004705E03.9———1—1
Percutaneous coronary interventionD062645———1—1
Body weightD001835EFO_0004338———1—1
Acute kidney injuryD058186HP_0001919N17———1—1
Chronic renal insufficiencyD051436N18———1—1
Show 3 more
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324I25.1—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501———12
NeoplasmsD009369C801———12
Triple negative breast neoplasmsD0647261————1
Renal cell carcinomaD0022921————1
Castration-resistant prostatic neoplasmsD0641291————1
Urologic neoplasmsD014571C64-C681————1
Non-small-cell lung carcinomaD0022891————1
Lung neoplasmsD008175C34.901————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug-related side effects and adverse reactionsD064420T88.7————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIOPROMIDE
INNiopromide
Description
Iopromide is a dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration. It has a role as a radioopaque medium, a nephrotoxic agent, a xenobiotic and an environmental contaminant. It is an organoiodine compound and a dicarboxylic acid diamide. It is functionally related to an isophthalamide and a glycerol.
Classification
Small molecule
Drug classiodine-containing contrast media
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COCC(=O)Nc1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I
Identifiers
PDB—
CAS-ID73334-07-3
RxCUI27781
ChEMBL IDCHEMBL1725
ChEBI ID63578
PubChem CID3736
DrugBankDB09156
UNII ID712BAC33MZ (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,800 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ultravist
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,234 adverse events reported
View more details